Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery - Drug Trials For Money - Paid Clinical Trials

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Conditions:   Carcinoma, Ovarian Epithelial;   Ovarian Neoplasms;   Ovarian Cancer;   Ovarian Serous Adenocarcinoma;   Fallopian Tube Neoplasms;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Peritoneal Cancer;   Peritoneal Carcinoma;   Peritoneal Neoplasms
Interventions:   Biological: Oregovomab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Placebo
Sponsors:   OncoQuest Pharmaceuticals Inc.;   Gynecologic Oncology Group;   Iqvia Pty Ltd
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 1, 2022 / by / in
Comments